Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial

Journal of Clinical Oncology

Volumn 30, Issue 2, 2012, Pages 134-141

  Wells, Samuel A ^a   Robinson, Bruce G ^b   Gagel, Robert F ^c   Dralle, Henning ^d   Fagin, James A ^e   Santoro, Massimo ^f   Baudin, Eric ^g   Elisei, Rossella ^h   Jarzab, Barbara ⁱ   Vasselli, James R ^j   Read, Jessica ^j   Langmuir, Peter ^j   Ryan, Anderson J ^k   Schlumberger, Martin J ^g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h UNIVERSITY OF PISA   (Italy)

ⁱ INSTITUTE OF ONCOLOGY   (Poland)

^j ASTRAZENECA   (United Kingdom)

^k UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VANDETANIB;

ABDOMINAL PAIN; ACNE; ADULT; APPETITE; ARTICLE; ASTHENIA; BACKACHE; BIOCHEMISTRY; CANCER GROWTH; CONTROLLED STUDY; COUGHING; DEATH; DERMATITIS; DIARRHEA; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRY SKIN; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; VOMITING;

EID: 84655175698     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.5040     Document Type: Article

References (29)

1. Hundahl SA, Fleming ID, Fremgen AM, et al: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 83:2638-2648, 1998 (Pubitemid 29019586)
2. Lakhani VT, You YN, Wells SA: The multiple endocrine neoplasia syndromes. Annu Rev Med 58:253-265, 2007 (Pubitemid 46706513)
3. Roman S, Lin R, Sosa JA: Prognosis of medullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134-2142, 2006 (Pubitemid 44665646)
4. Modigliani E, Cohen R, Campos JM, et al: Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: Results in 899 patients - The GETC Study Group, Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) 48:265-273, 1998 (Pubitemid 28137636)
5. Martins RG, Rajendran JG, Capell P, et al: Medullary thyroid cancer: Options for systemic therapy of metastatic disease? J Clin Oncol 24:1653-1655, 2006 (Pubitemid 46622135)
6. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al: Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 19:565-612, 2009
7. Donis-Keller H, Dou S, Chi D, et al: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856, 1993 (Pubitemid 23216611)
8. Mulligan LM, Kwok JB, Healey CS, et al: Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460, 1993 (Pubitemid 23179393)
9. Carlson KM, Dou S, Chi D, et al: Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 91:1579-1583, 1994 (Pubitemid 24059056)
10. Marsh DJ, Learoyd DL, Andrew SD, et al: Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 44:249-257, 1996 (Pubitemid 26063401)
11. Elisei R, Cosci B, Romei C, et al: Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study. J Clin Endocrinol Metab 93:682-687, 2008 (Pubitemid 351398539)
12. Carlomagno F, Vitagliano D, Guida T, et al: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290, 2002 (Pubitemid 36025251)
13. Carlomagno F, Anaganti S, Guida T, et al: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326-334, 2006 (Pubitemid 43338212)
14. Santoro M, Carlomagno F: Drug insight: Small molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab 2:42-52, 2006
15. Rodríguez-Antona C, Pallares J, Montero-Conde C, et al: Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 17:7-16, 2010
16. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655, 2002
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Wells SA Jr, Gosnell JE, Gagel RF, et al: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772, 2010
19. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
20. Whitehead J: The analysis of relapse clinical trials, with application to a comparison of two ulcer treatments. Stat Med 8:1439-1454, 1989
21. Weibull W: A statistical distribution function of wide applicability. J Appl Mech Trans 18:293-297, 1951
22. Vidal M, Wells S, Ryan A, et al: ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 65:3538-3541, 2005
23. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al: A Phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:3466-3469, 2007
24. Frank-Raue K, Fabel M, Delorme S, et al: Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 157:215-220, 2007 (Pubitemid 47233127)
25. Cohen EE, Rosen LS, Vokes EE, et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a Phase II study. J Clin Oncol 26:4708-4713, 2008
26. Gupta-Abramson V, Troxel AB, Nellore A, et al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719, 2008
27. Pennell NA, Daniels GH, Haddad RI, et al: A Phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18:317-323, 2008 (Pubitemid 351415790)
28. Schlumberger MJ, Elisei R, Bastholt L, et al: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801, 2009
29. Lam ET, Ringel MD, Kloos RT, et al: Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330, 2010